Acadia’s New CEO Receives Equity Awards in Inducement Grant

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced that on September 23, 2024, its Board of Directors granted Catherine Owen Adams, the newly appointed Chief Executive Officer, a one-time sign-on equity package. This award includes 353,261 stock options priced at $16.29 per share, Acadia’s closing price on September 23. These options will vest 25% after one year, with the remaining amount vesting monthly over the next three years. Additionally, she was awarded 160,763 performance stock units, which can be earned based on achieving shareholder return targets over three years, with potential payouts ranging from 0% to 150% of the target, subject to her continued service.

The awards were granted under Acadia’s 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), as part of an effort to attract and retain key leadership. These awards are designed to incentivize Adams' leadership and align her interests with those of shareholders.

Acadia Pharmaceuticals remains committed to advancing neuroscience breakthroughs, with a focus on conditions like Parkinson’s disease psychosis, Rett syndrome, Prader-Willi syndrome, and Alzheimer’s disease psychosis.